Clenoliximab
From Self-sufficiency
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Template:Infobox drug/mab source |
Target | CD4 |
Identifiers | |
ATC code | none |
Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2): 89.
- ↑ Hepburn, TW; Totoritis, MC; Davis, CB (2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis". Rheumatology (Oxford, England). 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs